The main objective of QLSCD is to identify the precursors of children’s social adaptation, school adjustment, and well-being throughout their developmental trajectory. This study has information on young children’s (now young adults) health, behaviour and many other aspects of their life.

The VLS is a long-term, large-scale, and multi-faceted longitudinal investigation of human aging. Incorporating biomedical approaches, leading-edge technologies, and epidemiological perspectives, the VLS evaluates and tracks actual cognitive, health, functional and lifestyle trajectories leading to outcomes that can be classified as normal, resilient, exceptional, impaired, or dementia. Our studies examine these differential brain and cognitive changes as a function of interactions among multiple “biomarkers” of both risk and protection. Among these dynamically interacting biomarkers are those representing selected aspects of biological, health, genetic, metabolic, vascular, lifestyle, physical fitness, cognitive activity, sex/gender, and demographic domains

The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.

The CARTaGENE (CaG) study is both a population-based biobank and the largest ongoing prospective health study of men and women in Quebec. CaG targeted the segment of the population that is most at risk of developing chronic disorders, that is 40-69 years of age, from six census metropolitan areas in Quebec. The sampling was stratified by age, sex and postal groups and is proportional to the density of the population in these areas. Over 43,000 participants consented to visiting 1 of 12 assessment sites where detailed health and socio-demographic information, physiological measures and biological samples (blood, serum and urine) were captured. Participants are followed-up based on linkage to governmental health administrative databases and direct reassessment through a web portal.

Last update 21/09/2017

General objectives of the NuAge Study:
1. To assess changes in dietary intakes of ageing men and women (foods, energy, macronutrients, micronutrients) and longterm exposure to functional foods from a qualitative and quantitative perspective;
2. To assess the influence of longstanding and current dietary habits and evolving food choices on changes in numerous markers of physical and cognitive status, functional autonomy and social functioning;
3. To assess the impact of age-related alterations in energy metabolism (utilisation and expenditure) and body composition, on changes in numerous markers of physical and cognitive status, functional autonomy and social functioning;
4. To assess the impact of individual (biological, psychological, health, functional, behavioural) and environmental determinants on dietary intakes.

The population is comprised of 1793 healthy men and women, selected from three age groups (68ヨ72, 73ヨ77, 78ヨ82) at recruitment. A total of 82.4% of the population is French speaking participants and a total of 14.3% is English speaking participants.

Last Update 21/09/2017

Alberta’s Tomorrow Project (ATP) is a longitudinal study tracking the health of 55,000 adults aged 35-69 years in this western Canadian province. ATP was launched in 2000 as a prospective cohort research platform to study the relationship between environmental, lifestyle, and genetic factors and the incidence of cancer and chronic diseases.

In 2008, ATP joined a nation-wide research platform called the Canadian Partnership for Tomorrow Project (CPTP) representing more than 300,000 participants from five provincial cohorts: Alberta, British Columbia, Ontario, Quebec and the Atlantic provinces (Prince Edward Island, New Brunswick, Newfoundland and Labrador, and Nova Scotia). Together, the consortium of five regional studies provides greater statistical power for research, as well as opportunities to examine geographical trends in health and wellbeing across Canada’s vast landscape.

The information contained herein is specific to the ATP cohort.

Last Update 21/09/2017

The CLSA will collect information on the changing biological, medical, psychological, social, lifestyle and economic aspects of people’s lives across Canada. These factors will be studied to understand how, individually and in combination, they have an impact in both maintaining health and in the development of disease and disability as people age

A total of 21,241 people from across Canada have agreed to take part in a telephone interview, once every three years.

An additional 30,097 people consented to participate in an in-home interview, and a visit to one of 11 Data Collection Sites across Canada where they take part in a range of physical assessments.

These participants were selected randomly, and were aged 45 to 85 when first contacted. The interviews and visits will take place once every three years over the 20-year course of the study

The study has entered its next phase where each individual recruited between 2010 and 2015 (baseline) will be re-contacted for the first follow-up. This will be conducted between 2015 and 2018. During this phase, the CLSA research team will collect the same type of information that was collected at baseline, along with several new measures that have been introduced.

Last update – 12/05/2017

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

  • Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
  • To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
  • To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
  • To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

Last update – 07/02/2017